Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Scraps ‘Most Favored Nation’ Rule To Lower Medicare Part B Drug Costs

Executive Summary

US Centers For Medicare and Medicaid Services doesn’t tip its hand on what, if anything, might replace the rule but says it is exploring ways to lower spending on Medicare Part B drugs.

You may also be interested in...



CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models

CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.

Importation, Pay-For-Delay Reform Backed By Biden Order; March-In Rights For Pricing Suggested

The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.

Drug Pricing Reform: Now It Is HHS Secretary Becerra’s Turn

After months of reticence about his Administration's plans for tackling drug pricing, Biden's executive order offers some clues about what might be in store and what kind of timeline they are working with. 

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS144769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel